Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

INTRODUCTION: The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A). METHODS: Pre-treatment BMD of 213 pati...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Markopoulos, Christos, Tzoracoleftherakis, Evagelos, Polychronis, Athanassios, Venizelos, Basileios, Dafni, Urania, Xepapadakis, Grigorios, Papadiamantis, John, Zobolas, Vasilios, Misitzis, John, Kalogerakos, Kyriakos, Sarantopoulou, Angeliki, Siasos, Nikolaos, Koukouras, Dimitrios, Antonopoulou, Zoh, Lazarou, Spyros, Gogas, Helen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2010
Konular:
Research article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2879572/
https://ncbi.nlm.nih.gov/pubmed/20398352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2565
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller